HU0101176A3 - Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them - Google Patents

Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HU0101176A3
HU0101176A3 HU0101176A HU0101176A HU0101176A3 HU 0101176 A3 HU0101176 A3 HU 0101176A3 HU 0101176 A HU0101176 A HU 0101176A HU 0101176 A HU0101176 A HU 0101176A HU 0101176 A3 HU0101176 A3 HU 0101176A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
inhibit matrix
degrading metalloproteinases
sulfonylamino derivatives
sulfonylamino
Prior art date
Application number
HU0101176A
Other languages
Hungarian (hu)
Other versions
HU0101176A2 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US1881998A priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to PCT/EP1999/000646 priority patent/WO1999042443A1/en
Publication of HU0101176A2 publication Critical patent/HU0101176A2/en
Publication of HU0101176A3 publication Critical patent/HU0101176A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
HU0101176A 1998-02-04 1999-02-02 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them HU0101176A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US1881998A true 1998-02-04 1998-02-04
PCT/EP1999/000646 WO1999042443A1 (en) 1998-02-04 1999-02-02 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Publications (2)

Publication Number Publication Date
HU0101176A2 HU0101176A2 (en) 2001-09-28
HU0101176A3 true HU0101176A3 (en) 2002-06-28

Family

ID=21789936

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101176A HU0101176A3 (en) 1998-02-04 1999-02-02 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (1) US6277987B1 (en)
EP (2) EP1918278A1 (en)
JP (1) JP4750272B2 (en)
KR (1) KR20010040698A (en)
CN (1) CN1195735C (en)
AU (1) AU747911B2 (en)
BR (1) BR9909322A (en)
CA (1) CA2318145C (en)
HU (1) HU0101176A3 (en)
ID (1) ID24957A (en)
IL (1) IL137465D0 (en)
NO (1) NO317977B1 (en)
NZ (1) NZ505968A (en)
PL (1) PL342009A1 (en)
RU (1) RU2208609C2 (en)
SK (1) SK11692000A3 (en)
TR (1) TR200002224T2 (en)
WO (1) WO1999042443A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756248B2 (en) * 1998-04-03 2003-01-09 Sankyo Company Limited Sulfonamide derivatives
JP2002538146A (en) 1999-03-03 2002-11-12 ザ プロクター アンド ギャンブル カンパニー Dihetero-substituted metalloprotease inhibitors
SK12452001A3 (en) * 1999-03-03 2002-04-04 The Procter & Gamble Company Metalloproteinase inhibitor creating compound, a pharmaceutical composition, process for preparing drug and a drug
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
WO2001023363A1 (en) * 1999-09-29 2001-04-05 Sankyo Company, Limited Sulfonamide derivatives
CN1418193A (en) * 2000-03-21 2003-05-14 宝洁公司 heterocyclic side chain containing metalloprotease inbibitors
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
CA2404002A1 (en) * 2000-03-24 2001-09-27 Methylgene Inc. Inhibitors of histone deacetylase
WO2001083431A1 (en) * 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Mmp-12 inhibitors
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
SE0100903D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (en) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
AT438618T (en) * 2001-12-14 2009-08-15 Exelixis Inc Inhibitors of human adam-10
EP1491190A4 (en) * 2002-03-27 2006-01-04 Shionogi & Co Decomposition inhibitor for extracellular matrix of cartilage
WO2003101382A2 (en) 2002-05-29 2003-12-11 Merck & Co., Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
SE0202539D0 (en) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
WO2005118529A2 (en) 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (en) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
EP1802331A2 (en) * 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
SE0403086D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7576222B2 (en) * 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
WO2007117451A2 (en) * 2006-03-31 2007-10-18 The Regents Of The University Of Michigan A pericellular collagenase directs the 3-dimensional development of white adipose tissue
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP1972617A1 (en) * 2007-03-19 2008-09-24 Bracco Imaging, S.P.A. Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
JP5490092B2 (en) 2008-03-24 2014-05-14 ノバルティス アーゲー Matrix metalloprotease inhibitors based on arylsulfonamides
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
EP2149568A1 (en) 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20151091A1 (en) * 2008-12-04 2015-09-05 Abbvie Inc APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ592801A (en) * 2008-12-05 2013-08-30 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ITTO20090648A1 (en) * 2009-08-19 2011-02-20 Istituto Naz Per La Ricerca Sul Cancro Adam17 inhibitors designed to modulate the release of soluble alcam (cd166) in cancer cells and their use in the therapeutic treatment of epithelial ovarian cancer (eoc)
US9023318B2 (en) 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1493665A1 (en) 1964-07-16 1969-02-06 Hoechst Ag Process for the cleavage of aromatic carboxamides
EP0639982A1 (en) 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
AT191468T (en) 1994-06-22 2000-04-15 British Biotech Pharm METALLOPROTEINASE INHIBITORS
US5977141A (en) 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
AT234291T (en) 1995-12-08 2003-03-15 Agouron Pharma METAL PROTEINASE INHIBITORS, THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR PHARMACEUTICAL USE AND METHOD FOR THE PRODUCTION THEREOF
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
SK282995B6 (en) * 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing same
BR9710841A (en) * 1996-05-17 1999-08-17 Warner Lambert Co Biphenyl sulfonamide matrix metallproteinase inhibitors
WO1997045402A1 (en) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Phenylsulfonamide derivatives
BR9712792A (en) 1996-08-28 1999-12-14 Procter & Gamble Bidentate metalloprotease inhibitors.
WO1998008822A1 (en) 1996-08-28 1998-03-05 The Procter & Gamble Company 1,3-diheterocyclic metalloprotease inhibitors
BR9712085A (en) 1996-08-28 2000-10-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
TR199900431T2 (en) 1996-08-28 1999-04-21 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
RU2203274C2 (en) 1996-08-28 2003-04-27 Дзе Проктер Энд Гэмбл Компани Spirocyclic inhibitors of metalloproteases
DE69718480T2 (en) 1996-08-28 2003-12-24 Procter & Gamble HETEROCYCLIC METALLOPROTEASE INHIBITORS
PT946166E (en) * 1996-12-17 2004-06-30 Warner Lambert Co USE OF MATRIX METALOPROTEINAS INHIBITORS FOR TREATING NEUROLOGICAL DISTURBLES AND PROMOTING WOUND HEALING
CN1243507A (en) * 1997-01-17 2000-02-02 法玛西雅厄普约翰美国公司 Bis-sulfonomides hydroxamic acids as MMP inhibitors
EP0973748A1 (en) 1997-04-01 2000-01-26 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
DE19719621A1 (en) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarboxylic acids
AU7294098A (en) 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719585A1 (en) 1997-05-09 1998-11-12 Hoechst Ag New N-sulphonyl-di:amino:carboxylic acid derivatives
PT877019E (en) 1997-05-09 2002-05-31 Hoechst Ag Substituted diaminocarboxylic acids
DE19719428A1 (en) 1997-05-12 1998-11-19 Hoechst Ag New N-sulphonyl-di:amino:carboxylic acid derivatives
US6423729B1 (en) 1997-07-22 2002-07-23 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
KR100352316B1 (en) * 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors

Also Published As

Publication number Publication date
CN1195735C (en) 2005-04-06
TR200002224T2 (en) 2000-12-21
PL342009A1 (en) 2001-05-07
AU2923599A (en) 1999-09-06
CA2318145A1 (en) 1999-08-26
ID24957A (en) 2000-08-31
EP1918278A1 (en) 2008-05-07
NZ505968A (en) 2003-03-28
US6277987B1 (en) 2001-08-21
KR20010040698A (en) 2001-05-15
SK11692000A3 (en) 2001-02-12
BR9909322A (en) 2000-12-05
JP2002503720A (en) 2002-02-05
HU0101176A2 (en) 2001-09-28
RU2208609C2 (en) 2003-07-20
CA2318145C (en) 2009-10-27
NO20003565L (en) 2000-10-03
NO317977B1 (en) 2005-01-17
EP1053226A1 (en) 2000-11-22
NO20003565D0 (en) 2000-07-11
JP4750272B2 (en) 2011-08-17
CN1290250A (en) 2001-04-04
IL137465D0 (en) 2001-07-24
AU747911B2 (en) 2002-05-30
WO1999042443A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
HU0101176A3 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
HU0103344A3 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them
HU0103376A3 (en) New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use
HU0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HK1039122A1 (en) Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
HU0102334A3 (en) Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound
IL138969D0 (en) Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL138799D0 (en) Benzamide and sulfonamide substituted aminoguanidine and alkoxyguanidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL155657A (en) Acylaminoalkyl-substituted benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions comprising them
IL140897D0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
HU0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HU0100489D0 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
IL143577D0 (en) Piperazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU9801089A3 (en) Benzenesulfonamide derivatives, process for their preparation, pharmaceutical compositions containing them
SI1118610T1 (en) Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
HU0303195A3 (en) O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them
HU0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HU0101234A3 (en) Betha-carboline derivatives, process for their preparation and pharmaceutical compositions thereof
HU0200343A3 (en) Phenylalaninol derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0104202A3 (en) Thiazole-derivatives, process for their preparation and pharmaceutical compositions containing them
HU0103077A3 (en) New benzothiadiazine derivatives, process for their preparation and pharmaceutical compositions containing them
DK0979816T3 (en) Hydroxamic acid derivatives, processes for their preparation and pharmaceutical compositions containing them
HU0003991D0 (en) Serotonin-reuptake inhibitor ciano-indole derivatives, process for their preparation and pharmaceutical compositions containing them